Crombez Eric's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed May 5, 2025
- Accession no.
- 0000950170-25-063792
- Filed
- May 5, 2025
- Trade date
- Apr 21-May 5, 2025
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $28.9K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crombez EricCIK 0001653052 | Officer (EVP and Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2025 | Common Stock | SSaleDisposed | −242 | $35.11 | −$8,496.62 | 71,680 | Direct | |
| May 5, 2025 | Common Stock | SSaleDisposed | −520 | $39.24 | −$20,404.8 | 71,530 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.